Evolving treatment patterns and outcomes among patients with metastatic urothelial carcinoma post-avelumab maintenance approval: insights from The US Oncology Network

H. Li , S. Sura , A. Babcock , L. Herms , J. Guo , P. Conkling , S. Franco , P. Singhal , R. Mamtani , M. Bupathi
{"title":"Evolving treatment patterns and outcomes among patients with metastatic urothelial carcinoma post-avelumab maintenance approval: insights from The US Oncology Network","authors":"H. Li ,&nbsp;S. Sura ,&nbsp;A. Babcock ,&nbsp;L. Herms ,&nbsp;J. Guo ,&nbsp;P. Conkling ,&nbsp;S. Franco ,&nbsp;P. Singhal ,&nbsp;R. Mamtani ,&nbsp;M. Bupathi","doi":"10.1016/j.esmorw.2024.100110","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The addition of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates into the metastatic urothelial cancer (mUC) treatment landscape has advanced therapeutic strategies beyond platinum-based chemotherapy (PBT). We evaluated real-world treatment patterns and overall survival (OS) among mUC patients during the period between maintenance avelumab (maintA) and enfortumab vedotin plus pembrolizumab approvals in the United States.</div></div><div><h3>Materials and methods</h3><div>This retrospective cohort study utilized structured and chart review data from iKnowMed, a United States community oncology electronic health record database, to identify adult mUC patients initiating first-line (1L) anticancer treatment (index date) between April 2020 and September 2022. Patients were followed from the index date until March 2023, the last patient visit, or death, whichever occurred first. Descriptive statistics were used to report treatment patterns. Kaplan–Meier methods were used to assess OS.</div></div><div><h3>Results</h3><div>A total of 597 patients initiated 1L treatments (ICI monotherapy: 47.9%, PBT: 40.7%, other: 11.4%). The median age at diagnosis was 74 years, and 76.9% were male. Among patients receiving 1L PBT, 39.5% received maintA. Among those who were not on prior treatment at the end of the follow-up, 32.7% and 11.3% of 1L-treated patients received second-line and third-line treatment. The median OS from the index date for 1L-treated patients was 11.8 months (95% confidence interval 10.4-14.2 months).</div></div><div><h3>Conclusions</h3><div>Despite the approval of maintenance therapy, prognoses for mUC patients remained poor. ICI monotherapy continues to be a common option in 1L. Many 1L patients did not have an opportunity to receive subsequent treatment, highlighting the continuing unmet need for mUC patients.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"7 ","pages":"Article 100110"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Real World Data and Digital Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949820124000882","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The addition of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates into the metastatic urothelial cancer (mUC) treatment landscape has advanced therapeutic strategies beyond platinum-based chemotherapy (PBT). We evaluated real-world treatment patterns and overall survival (OS) among mUC patients during the period between maintenance avelumab (maintA) and enfortumab vedotin plus pembrolizumab approvals in the United States.

Materials and methods

This retrospective cohort study utilized structured and chart review data from iKnowMed, a United States community oncology electronic health record database, to identify adult mUC patients initiating first-line (1L) anticancer treatment (index date) between April 2020 and September 2022. Patients were followed from the index date until March 2023, the last patient visit, or death, whichever occurred first. Descriptive statistics were used to report treatment patterns. Kaplan–Meier methods were used to assess OS.

Results

A total of 597 patients initiated 1L treatments (ICI monotherapy: 47.9%, PBT: 40.7%, other: 11.4%). The median age at diagnosis was 74 years, and 76.9% were male. Among patients receiving 1L PBT, 39.5% received maintA. Among those who were not on prior treatment at the end of the follow-up, 32.7% and 11.3% of 1L-treated patients received second-line and third-line treatment. The median OS from the index date for 1L-treated patients was 11.8 months (95% confidence interval 10.4-14.2 months).

Conclusions

Despite the approval of maintenance therapy, prognoses for mUC patients remained poor. ICI monotherapy continues to be a common option in 1L. Many 1L patients did not have an opportunity to receive subsequent treatment, highlighting the continuing unmet need for mUC patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study Core variables for real-world clinicogenomic data collection in precision oncology Cancer in public figures, 2010-2020 Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1